NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.7620
-0.0083 (-1.08%)
At close: May 19, 2026, 4:00 PM EDT
0.7550
-0.0070 (-0.92%)
After-hours: May 19, 2026, 4:50 PM EDT

NeuroSense Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-11.13-10.21-10.11-10.49-4.04
Depreciation & Amortization
0.020.020.020.010
Stock-Based Compensation
2.140.561.541.734.16
Other Adjustments
-0.050.28-1.720.04-1.93
Change in Receivables
-----0.2
Changes in Accounts Payable
-0.36-0.30.960.46-0.02
Changes in Accrued Expenses
1.270.260.930.610.49
Changes in Other Operating Activities
0.44-0.740.020.03-
Operating Cash Flow
-7.67-10.14-8.35-7.62-1.54
Capital Expenditures
-0.01-0-0.03-0.07-0.02
Proceeds from Sale of Investments
--3.5-3.5-
Other Investing Activities
-0-0-0.02-
Investing Cash Flow
-0.0103.47-3.59-0.02
Long-Term Debt Issued
----0.8
Net Long-Term Debt Issued (Repaid)
----0.8
Issuance of Common Stock
4.5511.34.343.8711.1
Net Common Stock Issued (Repurchased)
4.5511.34.343.8711.1
Other Financing Activities
-0.12-0.39-0.36-0.1-
Financing Cash Flow
4.4310.913.983.7711.9
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.04-0.040.01-0.090.02
Net Cash Flow
-3.210.74-0.9-7.5210.36
Free Cash Flow
-7.68-10.14-8.38-7.69-1.56
Free Cash Flow Per Share
-0.30-0.54-0.61-0.67-0.25
Levered Free Cash Flow
-9.77-10.97-8.2-9.46-2.78
Unlevered Free Cash Flow
-9.73-10.66-10.14-9.52-5.12
Updated Mar 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q